MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

In 2017, the Food and Drug Administration (FDA) approved ocrelizumab (Ocrevus) as the first disease-modifying therapy for people with progressive MS. As the National MS Society explains ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

"This two-stage model is incorrect," he pointed out. "What we call secondary progressive MS is very likely the same process that occurs once relapsing activity is suppressed by highly effective ...

However, benign MS may change to a progressive form of MS. Multiple sclerosis (MS) can vary greatly from person to person. Benign MS is a term sometimes used to describe a form of MS in which a ...

Decades of subtle health changes went by without answers. When worsening disability led Roger to a multiple sclerosis (MS) ...

Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS).

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.